Difference between revisions of "Anal cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 24: Line 24:
 
==Capecitabine, Mitomycin, RT {{#subobject:6a7b17 |Regimen=1}}==
 
==Capecitabine, Mitomycin, RT {{#subobject:6a7b17 |Regimen=1}}==
  
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:9368b2|Variant=1}}===
 
===Regimen {{#subobject:9368b2|Variant=1}}===
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
Line 35: Line 36:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Capecitabine (Xeloda)]] 825 mg/m<sup>2</sup> PO twice per day on radiation days
 
*[[Capecitabine (Xeloda)]] 825 mg/m<sup>2</sup> PO twice per day on radiation days
Line 42: Line 44:
  
 
'''6-week course'''
 
'''6-week course'''
 +
</div></div>
 
===References===
 
===References===
 
# '''EXTRA:''' Glynne-Jones R, Meadows H, Wan S, Gollins S, Leslie M, Levine E, McDonald AC, Myint S, Samuel L, Sebag-Montefiore D; National Cancer Research Institute Anal Sub Group; NCRI Colorectal Clinical Oncology Group. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):119-26. Epub 2008 May 9. [https://doi.org/10.1016/S0360-3016(07)04703-7 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/18472366 PubMed]
 
# '''EXTRA:''' Glynne-Jones R, Meadows H, Wan S, Gollins S, Leslie M, Levine E, McDonald AC, Myint S, Samuel L, Sebag-Montefiore D; National Cancer Research Institute Anal Sub Group; NCRI Colorectal Clinical Oncology Group. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):119-26. Epub 2008 May 9. [https://doi.org/10.1016/S0360-3016(07)04703-7 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/18472366 PubMed]
Line 48: Line 51:
  
 
CF & RT: '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil, '''<u>R</u>'''adiation '''<u>T</u>'''herapy
 
CF & RT: '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil, '''<u>R</u>'''adiation '''<u>T</u>'''herapy
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:6d1962 |Variant=1}}===
 
===Regimen {{#subobject:6d1962 |Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 83: Line 87:
 
''<sup>1</sup>Reported efficacy for RTOG 98-11 is based on the 2012 update.''<br>
 
''<sup>1</sup>Reported efficacy for RTOG 98-11 is based on the 2012 update.''<br>
 
''Included for reference purposes only.''
 
''Included for reference purposes only.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Cisplatin (Platinol)]]
 
*[[Cisplatin (Platinol)]]
Line 89: Line 94:
 
*[[External beam radiotherapy]]
 
*[[External beam radiotherapy]]
  
 +
</div></div>
 
===References===
 
===References===
 
#Doci R, Zucali R, La Monica G, Meroni E, Kenda R, Eboli M, Lozza L. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol. 1996 Dec;14(12):3121-5. [https://doi.org/10.1200/jco.1996.14.12.3121 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8955657/ PubMed]
 
#Doci R, Zucali R, La Monica G, Meroni E, Kenda R, Eboli M, Lozza L. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol. 1996 Dec;14(12):3121-5. [https://doi.org/10.1200/jco.1996.14.12.3121 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8955657/ PubMed]
Line 98: Line 104:
 
==Fluorouracil, Mitomycin, RT {{#subobject:744af9|Regimen=1}}==
 
==Fluorouracil, Mitomycin, RT {{#subobject:744af9|Regimen=1}}==
  
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen variant #1, 3750/12/45 {{#subobject:6hdc9c |Variant=1}}===
 
===Regimen variant #1, 3750/12/45 {{#subobject:6hdc9c |Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 114: Line 121:
 
|}
 
|}
 
''Because there were a few different schedules used in UKCCCR Anal Cancer Trial Working Party 1996 and the update (Northover et al. 2010), there is some variability in potential schedules.''
 
''Because there were a few different schedules used in UKCCCR Anal Cancer Trial Working Party 1996 and the update (Northover et al. 2010), there is some variability in potential schedules.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 3750 mg/m<sup>2</sup>)
 
*[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 3750 mg/m<sup>2</sup>)
Line 121: Line 129:
  
 
'''28-day cycle for 2 cycles'''
 
'''28-day cycle for 2 cycles'''
−
 
+
</div></div><br>
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen variant #2, 3750/15/45 {{#subobject:cf4334 |Variant=1}}===
 
===Regimen variant #2, 3750/15/45 {{#subobject:cf4334 |Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 138: Line 147:
 
|}
 
|}
 
''Note: mitomycin is only given with cycle 1.''
 
''Note: mitomycin is only given with cycle 1.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 3750 mg/m<sup>2</sup>)
 
*[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 3750 mg/m<sup>2</sup>)
Line 146: Line 156:
  
 
'''28-day cycle for 2 cycles'''
 
'''28-day cycle for 2 cycles'''
−
 
+
</div></div><br>
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen variant #3, 4000/10/45 {{#subobject:8659c6 |Variant=1}}===
 
===Regimen variant #3, 4000/10/45 {{#subobject:8659c6 |Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 169: Line 180:
 
|}
 
|}
 
''<sup>1</sup>Reported efficacy for RTOG 98-11 is based on the 2012 update.''
 
''<sup>1</sup>Reported efficacy for RTOG 98-11 is based on the 2012 update.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)
 
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)
Line 176: Line 188:
  
 
'''28-day cycle for 2 cycles'''
 
'''28-day cycle for 2 cycles'''
−
 
+
</div></div><br>
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen variant #4, 4000/12/45 {{#subobject:63839c |Variant=1}}===
 
===Regimen variant #4, 4000/12/45 {{#subobject:63839c |Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 193: Line 206:
 
|}
 
|}
 
''Because there were a few different schedules used in UKCCCR Anal Cancer Trial Working Party 1996 and the update (Northover et al. 2010), there is some variability in potential schedules.''
 
''Because there were a few different schedules used in UKCCCR Anal Cancer Trial Working Party 1996 and the update (Northover et al. 2010), there is some variability in potential schedules.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1, '''initiated at least 2 hours before the first radiation fraction''' (total dose per cycle: 4000 mg/m<sup>2</sup>)
 
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1, '''initiated at least 2 hours before the first radiation fraction''' (total dose per cycle: 4000 mg/m<sup>2</sup>)
Line 200: Line 214:
  
 
'''28-day cycle for 2 cycles'''
 
'''28-day cycle for 2 cycles'''
−
 
+
</div></div><br>
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen variant #5, 4000/12/50.4 {{#subobject:6382ac |Variant=1}}===
 
===Regimen variant #5, 4000/12/50.4 {{#subobject:6382ac |Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 216: Line 231:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)
 
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)
Line 223: Line 239:
  
 
'''28-day cycle for 2 cycles'''
 
'''28-day cycle for 2 cycles'''
 +
</div>
 +
<div class="toccolours" style="background-color:#cbd5e7">
 
====Subsequent treatment====
 
====Subsequent treatment====
 
*[[#Cisplatin_.26_Fluorouracil_.28CF.29_88|CF]] maintenance versus [[#Observation_88|no further treatment]]
 
*[[#Cisplatin_.26_Fluorouracil_.28CF.29_88|CF]] maintenance versus [[#Observation_88|no further treatment]]
  
 +
</div></div>
 
===References===
 
===References===
 
# '''ECOG E1289:''' Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, Quivey J, Rotman M, Kerman H, Coia L, Murray K; RTOG; ECOG. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996 Sep;14(9):2527-39. [https://doi.org/10.1200/JCO.1996.14.9.2527 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/8823332 PubMed]
 
# '''ECOG E1289:''' Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, Quivey J, Rotman M, Kerman H, Coia L, Murray K; RTOG; ECOG. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996 Sep;14(9):2527-39. [https://doi.org/10.1200/JCO.1996.14.9.2527 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/8823332 PubMed]
Line 237: Line 256:
 
==Radiation therapy {{#subobject:f4d6d6|Regimen=1}}==
 
==Radiation therapy {{#subobject:f4d6d6|Regimen=1}}==
  
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:57260e |Variant=1}}===
 
===Regimen {{#subobject:57260e |Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 253: Line 273:
 
|}
 
|}
 
''Inferior to combined modality therapy; included for reference purposes only.''
 
''Inferior to combined modality therapy; included for reference purposes only.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Radiotherapy====
 
====Radiotherapy====
 
*[[External beam radiotherapy]]
 
*[[External beam radiotherapy]]
  
 +
</div></div>
 
===References===
 
===References===
 
# '''ACT I:''' Northover JMA, Arnott SJ, Cunningham D, Gallagher J, Gray R, Hardcastle J, Houghton J, James RD, Lennon TA, Meadows HM, Mossman J, Morgan DAL, Plowman PN, Slevin M; UKCCCR Anal Cancer Trial Working Party; UK Co-ordinating Committee on Cancer Research. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996 Oct 19;348(9034):1049-54. [https://doi.org/10.1016/S0140-6736(96)03409-5 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/8874455 PubMed]
 
# '''ACT I:''' Northover JMA, Arnott SJ, Cunningham D, Gallagher J, Gray R, Hardcastle J, Houghton J, James RD, Lennon TA, Meadows HM, Mossman J, Morgan DAL, Plowman PN, Slevin M; UKCCCR Anal Cancer Trial Working Party; UK Co-ordinating Committee on Cancer Research. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996 Oct 19;348(9034):1049-54. [https://doi.org/10.1016/S0140-6736(96)03409-5 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/8874455 PubMed]
Line 263: Line 285:
 
==Cisplatin & Fluorouracil (CF) {{#subobject:f83c8e|Regimen=1}}==
 
==Cisplatin & Fluorouracil (CF) {{#subobject:f83c8e|Regimen=1}}==
  
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen variant #1, 100/5000 every 4 weeks {{#subobject:88896f |Variant=1}}===
 
===Regimen variant #1, 100/5000 every 4 weeks {{#subobject:88896f |Variant=1}}===
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
Line 274: Line 297:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 2
 
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 2
Line 279: Line 303:
  
 
'''28-day cycles'''
 
'''28-day cycles'''
−
 
+
</div></div><br>
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen variant #2, 60/4000 every 3 weeks {{#subobject:77796f |Variant=1}}===
 
===Regimen variant #2, 60/4000 every 3 weeks {{#subobject:77796f |Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 295: Line 320:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
 
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
Line 301: Line 327:
 
'''21-day cycles'''
 
'''21-day cycles'''
  
 +
</div></div>
 
===References===
 
===References===
 
# Faivre C, Rougier P, Ducreux M, Mitry E, Lusinchi A, Lasser P, Elias D, Eschwege F. [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. Bull Cancer. 1999 Oct;86(10):861-5. [http://www.jle.com/en/revues/medecine/bdc/e-docs/00/01/12/15/resume.phtml link to original article & English summary] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/10572237 PubMed]
 
# Faivre C, Rougier P, Ducreux M, Mitry E, Lusinchi A, Lasser P, Elias D, Eschwege F. [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. Bull Cancer. 1999 Oct;86(10):861-5. [http://www.jle.com/en/revues/medecine/bdc/e-docs/00/01/12/15/resume.phtml link to original article & English summary] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/10572237 PubMed]
Line 308: Line 335:
 
==Carboplatin & Paclitaxel (CP) {{#subobject:1a2b3c|Regimen=1}}==
 
==Carboplatin & Paclitaxel (CP) {{#subobject:1a2b3c|Regimen=1}}==
  
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:88896f |Variant=1}}===
 
===Regimen {{#subobject:88896f |Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 323: Line 351:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
 
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
Line 329: Line 358:
 
'''28-day cycles'''
 
'''28-day cycles'''
  
 +
</div></div>
 
===References===
 
===References===
 
<!-- # '''Abstract:''' Sclafani F et al. [InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin (CDDP) plus 5-fluorouracil (5-FU) versus carboplatin (CBDCA) plus weekly paclitaxel (PTX) in patients with inoperable locally recurrent (ILR) or metastatic disease]. Journal of Clinical Oncology. 2015 33:3_suppl, TPS792-TPS792. [https://doi.org/10.1200/jco.2015.33.3_suppl.tps792 link to abstract] '''contains dosing details in abstract''' -->
 
<!-- # '''Abstract:''' Sclafani F et al. [InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin (CDDP) plus 5-fluorouracil (5-FU) versus carboplatin (CBDCA) plus weekly paclitaxel (PTX) in patients with inoperable locally recurrent (ILR) or metastatic disease]. Journal of Clinical Oncology. 2015 33:3_suppl, TPS792-TPS792. [https://doi.org/10.1200/jco.2015.33.3_suppl.tps792 link to abstract] '''contains dosing details in abstract''' -->
Line 337: Line 367:
  
 
mDCF: '''<u>m</u>'''odified '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
 
mDCF: '''<u>m</u>'''odified '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:323b13|Variant=1}}===
 
===Regimen {{#subobject:323b13|Variant=1}}===
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
Line 348: Line 379:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Docetaxel (Taxotere)]] 40 mg/m<sup>2</sup> IV once on day 1
 
*[[Docetaxel (Taxotere)]] 40 mg/m<sup>2</sup> IV once on day 1
Line 355: Line 387:
 
'''14-day cycle for 8 cycles'''
 
'''14-day cycle for 8 cycles'''
  
 +
</div></div>
 
===References===
 
===References===
 
# '''Epitopes-HPV02:''' Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2018 Aug;19(8):1094-1106. Epub 2018 Jul 2. [https://doi.org/10.1016/S1470-2045(18)30321-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30042063 PubMed] NCT02402842
 
# '''Epitopes-HPV02:''' Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2018 Aug;19(8):1094-1106. Epub 2018 Jul 2. [https://doi.org/10.1016/S1470-2045(18)30321-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30042063 PubMed] NCT02402842
Line 361: Line 394:
 
==Nivolumab monotherapy {{#subobject:09c0df|Regimen=1}}==
 
==Nivolumab monotherapy {{#subobject:09c0df|Regimen=1}}==
  
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:f2c946|Variant=1}}===
 
===Regimen {{#subobject:f2c946|Variant=1}}===
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
Line 372: Line 406:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Immunotherapy====
 
====Immunotherapy====
 
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1
 
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1
  
 
'''14-day cycles'''
 
'''14-day cycles'''
 +
</div></div>
 
===References===
 
===References===
 
# '''NCI9673:''' Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Apr;18(4):446-453. Epub 2017 Feb 18. [https://doi.org/10.1016/S1470-2045(17)30104-3 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809128/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28223062 PubMed] NCT02314169
 
# '''NCI9673:''' Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Apr;18(4):446-453. Epub 2017 Feb 18. [https://doi.org/10.1016/S1470-2045(17)30104-3 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809128/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28223062 PubMed] NCT02314169
Line 381: Line 417:
 
==Pembrolizumab monotherapy {{#subobject:82c0df|Regimen=1}}==
 
==Pembrolizumab monotherapy {{#subobject:82c0df|Regimen=1}}==
  
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:f2c123|Variant=1}}===
 
===Regimen {{#subobject:f2c123|Variant=1}}===
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
Line 392: Line 429:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Immunotherapy====
 
====Immunotherapy====
 
*[[Pembrolizumab (Keytruda)]] 10 mg/kg IV once on day 1
 
*[[Pembrolizumab (Keytruda)]] 10 mg/kg IV once on day 1
Line 397: Line 435:
 
'''14-day cycle for up to 52 cycles (2 years)'''
 
'''14-day cycle for up to 52 cycles (2 years)'''
  
 +
</div></div>
 
===References===
 
===References===
 
# '''KEYNOTE-028:''' Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017 May 1;28(5):1036-1041. [https://doi.org/10.1093/annonc/mdx029 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406758/ link to PMC article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/28453692 PubMed] NCT02054806
 
# '''KEYNOTE-028:''' Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017 May 1;28(5):1036-1041. [https://doi.org/10.1093/annonc/mdx029 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406758/ link to PMC article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/28453692 PubMed] NCT02054806

Revision as of 23:39, 8 October 2022

Back to Top

Section editor transclusions

9 regimens on this page
13 variants on this page


Guidelines

ESMO

Older

NCCN

Definitive chemoradiotherapy for locally advanced disease

Capecitabine, Mitomycin, RT

Regimen

Study Years of enrollment Evidence
Glynne-Jones et al. 2008 (EXTRA) 2004-2006 Phase 2

Chemotherapy

Radiotherapy

6-week course

References

  1. EXTRA: Glynne-Jones R, Meadows H, Wan S, Gollins S, Leslie M, Levine E, McDonald AC, Myint S, Samuel L, Sebag-Montefiore D; National Cancer Research Institute Anal Sub Group; NCRI Colorectal Clinical Oncology Group. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):119-26. Epub 2008 May 9. link to original article contains dosing details in abstract PubMed

Cisplatin & Fluorouracil (CF) & RT

CF & RT: Cisplatin, Fluorouracil, Radiation Therapy

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Doci et al. 1996 1991-1995 Phase 2
Ajani et al. 2008 (RTOG 98-11) 1998-2005 Phase 3 (E-switch-ic) Fluorouracil, Mitomycin, RT Seems to have inferior OS1
Peiffert et al. 2012 (ACCORD 03) 1999-2005 Non-randomized portion of phase 3 RCT
James et al. 2013 (ACT II) 2001-2008 Phase 3 (E-switch-ic) Fluorouracil, Mitomycin, RT Did not meet primary endpoint of CR rate at 26 weeks

1Reported efficacy for RTOG 98-11 is based on the 2012 update.
Included for reference purposes only.

Chemotherapy

Radiotherapy

References

  1. Doci R, Zucali R, La Monica G, Meroni E, Kenda R, Eboli M, Lozza L. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol. 1996 Dec;14(12):3121-5. link to original article PubMed
  2. RTOG 98-11: Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008 Apr 23;299(16):1914-21. link to original article contains dosing details in manuscript PubMed NCT00003596
    1. Update: Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012 Dec 10;30(35):4344-51. Epub 2012 Nov 13. link to original article link to PMC article PubMed
  3. ACCORD 03: Peiffert D, Tournier-Rangeard L, Gérard JP, Lemanski C, François E, Giovannini M, Cvitkovic F, Mirabel X, Bouché O, Luporsi E, Conroy T, Montoto-Grillot C, Mornex F, Lusinchi A, Hannoun-Lévi JM, Seitz JF, Adenis A, Hennequin C, Denis B, Ducreux M. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012 Jun 1;30(16):1941-8. Epub 2012 Apr 23. Erratum in: J Clin Oncol. 2012 Nov 1;30(31):3903. link to original article PubMed NCT00003652
  4. ACT II: James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial. Lancet Oncol. 2013 May;14(6):516-24. Epub 2013 Apr 9. link to original article contains dosing details in manuscript PubMed NCT00025090

Fluorouracil, Mitomycin, RT

Regimen variant #1, 3750/12/45

Study Years of enrollment Evidence Comparator Comparative Efficacy
Northover et al. 1996 (ACT I) 1987-1994 Phase 3 (E-esc) Radiation Superior local failure rate

Because there were a few different schedules used in UKCCCR Anal Cancer Trial Working Party 1996 and the update (Northover et al. 2010), there is some variability in potential schedules.

Chemotherapy

  • Fluorouracil (5-FU) 750 mg/m2/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 3750 mg/m2)
  • Mitomycin (Mutamycin) 12 mg/m2 (maximum dose of 20 mg) IV bolus once on day 1

Radiotherapy

  • Concurrent radiation therapy: 1.8 or 2.25 Gy fractions x 20 or 25 fractions (total dose: 45 Gy), given over 4 to 5 weeks; see Northover et al. 2010 for details, including information about boost radiation therapy

28-day cycle for 2 cycles


Regimen variant #2, 3750/15/45

Study Years of enrollment Evidence Comparator Comparative Efficacy
Bartelink et al. 1997 (EORTC 22861) 1987-1994 Phase 3 (E-esc) Radiation Superior local failure rate

Note: mitomycin is only given with cycle 1.

Chemotherapy

Radiotherapy

28-day cycle for 2 cycles


Regimen variant #3, 4000/10/45

Study Years of enrollment Evidence Comparator Comparative Efficacy
Flam et al. 1996 (ECOG E1289) 1988-1991 Phase 3 (C) 5-FU & RT Superior DFS
Ajani et al. 2008 (RTOG 98-11) 1998-2005 Phase 3 (C) CF & RT Seems to have superior OS1

1Reported efficacy for RTOG 98-11 is based on the 2012 update.

Chemotherapy

  • Fluorouracil (5-FU) 1000 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m2)
  • Mitomycin (Mutamycin) 10 mg/m2 (maximum dose of 20 mg) IV bolus once on day 1

Radiotherapy

  • Concurrent radiation therapy; at a minimum: 1.8 Gy per day x 25 fractions (total dose: 45 Gy), given over 5 weeks; see articles for additional details

28-day cycle for 2 cycles


Regimen variant #4, 4000/12/45

Study Years of enrollment Evidence Comparator Comparative Efficacy
Northover et al. 1996 (ACT I) 1987-1994 Phase 3 (E-esc) Radiation Superior local failure rate

Because there were a few different schedules used in UKCCCR Anal Cancer Trial Working Party 1996 and the update (Northover et al. 2010), there is some variability in potential schedules.

Chemotherapy

  • Fluorouracil (5-FU) 1000 mg/m2/day IV continuous infusion over 96 hours, started on day 1, initiated at least 2 hours before the first radiation fraction (total dose per cycle: 4000 mg/m2)
  • Mitomycin (Mutamycin) 12 mg/m2 (maximum dose of 20 mg) IV bolus once on day 1

Radiotherapy

  • Concurrent radiation therapy: 1.8 or 2.25 Gy fractions x 20 or 25 fractions (total dose: 45 Gy), given over 4 to 5 weeks; see Northover et al. 2010 for details, including information about boost radiation therapy

28-day cycle for 2 cycles


Regimen variant #5, 4000/12/50.4

Study Years of enrollment Evidence Comparator Comparative Efficacy
James et al. 2013 (ACT II) 2001-2008 Phase 3 (C) Cisplatin, Fluorouracil, RT Did not meet primary endpoint of CR rate at 26 weeks

Chemotherapy

  • Fluorouracil (5-FU) 1000 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m2)
  • Mitomycin (Mutamycin) 12 mg/m2 (maximum dose of 20 mg) IV bolus once on day 1

Radiotherapy

  • Concurrent radiation therapy: 1.8 Gy per day x 28 fractions (total dose: 50.4 Gy), given over 5.5 weeks; see paper for details

28-day cycle for 2 cycles

Subsequent treatment

References

  1. ECOG E1289: Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, Quivey J, Rotman M, Kerman H, Coia L, Murray K; RTOG; ECOG. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996 Sep;14(9):2527-39. link to original article contains dosing details in manuscript PubMed
  2. ACT I: Northover JMA, Arnott SJ, Cunningham D, Gallagher J, Gray R, Hardcastle J, Houghton J, James RD, Lennon TA, Meadows HM, Mossman J, Morgan DAL, Plowman PN, Slevin M; UKCCCR Anal Cancer Trial Working Party; UK Co-ordinating Committee on Cancer Research. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996 Oct 19;348(9034):1049-54. link to original article contains dosing details in manuscript PubMed
    1. Update: Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, Jitlal M, Ledermann J. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010 Mar 30;102(7):1123-8. Epub 2010 Mar 16. link to original article contains dosing details in manuscript link to PMC article PubMed content property of HemOnc.org
  3. EORTC 22861: Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M; European Organisation for Research and Treatment of Cancer Radiotherapy Group; EORTC Gastrointestinal Cooperative Group. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organisation for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997 May;15(5):2040-9. link to original article contains dosing details in abstract PubMed
  4. RTOG 98-11: Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008 Apr 23;299(16):1914-21. link to original article contains dosing details in manuscript PubMed NCT00003596
    1. Update: Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012 Dec 10;30(35):4344-51. Epub 2012 Nov 13. link to original article link to PMC article PubMed
  5. ACT II: James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial. Lancet Oncol. 2013 May;14(6):516-24. Epub 2013 Apr 9. link to original article contains dosing details in manuscript PubMed NCT00025090

Radiation therapy

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Northover et al. 1996 (ACT I) 1987-1994 Phase 3 (C) Fluorouracil, Mitomycin, RT Inferior local failure rate

Inferior to combined modality therapy; included for reference purposes only.

Radiotherapy

References

  1. ACT I: Northover JMA, Arnott SJ, Cunningham D, Gallagher J, Gray R, Hardcastle J, Houghton J, James RD, Lennon TA, Meadows HM, Mossman J, Morgan DAL, Plowman PN, Slevin M; UKCCCR Anal Cancer Trial Working Party; UK Co-ordinating Committee on Cancer Research. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996 Oct 19;348(9034):1049-54. link to original article contains dosing details in manuscript PubMed
    1. Update: Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, Jitlal M, Ledermann J. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010 Mar 30;102(7):1123-8. Epub 2010 Mar 16. link to original article contains dosing details in manuscript link to PMC article PubMed content property of HemOnc.org

Metastatic disease, first-line therapy

Cisplatin & Fluorouracil (CF)

Regimen variant #1, 100/5000 every 4 weeks

Study Years of enrollment Evidence
Faivre et al. 1999 NR in abstract Pilot, <20 patients reported

Chemotherapy

28-day cycles


Regimen variant #2, 60/4000 every 3 weeks

Study Years of enrollment Evidence Comparator Comparative Efficacy
Rao et al. 2020 (InterAACT) 2013-2017 Randomized Phase 2 (C) Carboplatin & Paclitaxel Did not meet primary endpoint of ORR

Chemotherapy

21-day cycles

References

  1. Faivre C, Rougier P, Ducreux M, Mitry E, Lusinchi A, Lasser P, Elias D, Eschwege F. [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. Bull Cancer. 1999 Oct;86(10):861-5. link to original article & English summary contains dosing details in abstract PubMed
  2. InterAAct: Rao S, Sclafani F, Eng C, Adams RA, Guren MG, Sebag-Montefiore D, Benson A, Bryant A, Peckitt C, Segelov E, Roy A, Seymour MT, Welch J, Saunders MP, Muirhead R, O'Dwyer P, Bridgewater J, Bhide S, Glynne-Jones R, Arnold D, Cunningham D. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. J Clin Oncol. 2020 Aug 1;38(22):2510-2518. Epub 2020 Jun 12. link to original article link to PMC article PubMed NCT02051868

Carboplatin & Paclitaxel (CP)

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Rao et al. 2020 (InterAACT) 2013-2017 Randomized Phase 2 (E-switch-ic) CF Did not meet primary endpoint of ORR

Chemotherapy

28-day cycles

References

  1. InterAAct: Rao S, Sclafani F, Eng C, Adams RA, Guren MG, Sebag-Montefiore D, Benson A, Bryant A, Peckitt C, Segelov E, Roy A, Seymour MT, Welch J, Saunders MP, Muirhead R, O'Dwyer P, Bridgewater J, Bhide S, Glynne-Jones R, Arnold D, Cunningham D. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. J Clin Oncol. 2020 Aug 1;38(22):2510-2518. Epub 2020 Jun 12. link to original article link to PMC article PubMed NCT02051868
  2. ECOG-ACRIN EA2176: NCT04444921

mDCF

mDCF: modified Docetaxel, Cisplatin, Fluorouracil

Regimen

Study Years of enrollment Evidence
Kim et al. 2018 (Epitopes-HPV02) 2014-2016 Phase 2

Chemotherapy

14-day cycle for 8 cycles

References

  1. Epitopes-HPV02: Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2018 Aug;19(8):1094-1106. Epub 2018 Jul 2. link to original article PubMed NCT02402842

Metastatic disease, subsequent lines of therapy

Nivolumab monotherapy

Regimen

Study Years of enrollment Evidence
Morris et al. 2017 (NCI9673) 2015 Phase 2

Immunotherapy

14-day cycles

References

  1. NCI9673: Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Apr;18(4):446-453. Epub 2017 Feb 18. link to original article link to PMC article PubMed NCT02314169

Pembrolizumab monotherapy

Regimen

Study Years of enrollment Evidence
Ott et al. 2017a (KEYNOTE-028) 2014 Phase 1b, >20 pts in this subgroup

Immunotherapy

14-day cycle for up to 52 cycles (2 years)

References

  1. KEYNOTE-028: Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017 May 1;28(5):1036-1041. link to original article link to PMC article contains dosing details in abstract PubMed NCT02054806
Retrieved from "https://hemonc.org/w/index.php?title=Anal_cancer&oldid=62867"